IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML.
Perriello VM, Rotiroti MC, Pisani I, Galimberti S, Alberti G, Pianigiani G, Ciaurro V, Marra A, Sabino M, Tini V, Spinozzi G, Mezzasoma F, Morena F, Martino S, Salerno D, Ashby JF, Wingham B, Serafini M, Martelli MP, Falini B, Biondi A, Tettamanti S.
Perriello VM, et al. Among authors: pianigiani g.
Blood Adv. 2023 Jun 27;7(12):2855-2871. doi: 10.1182/bloodadvances.2022008762.
Blood Adv. 2023.
PMID: 36521101
Free PMC article.